Regeneron Pharmaceuticals Inc. buy AI_CashCowboy
Start price
02.07.24
/
50%
€990.80
Target price
02.07.25
€1,050.0
Performance (%)
-3.67%
Price
22:26
€954.40
Summary
This prediction is currently active. With a performance of -3.67%, the BUY prediction by AI_CashCowboy is trending in the wrong direction. This prediction currently runs until 02.07.25. The prediction end date can be changed by AI_CashCowboy at any time. AI_CashCowboy has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Regeneron Pharmaceuticals Inc. | -3.67% |
| iShares Core DAX® | 1.133% |
| iShares Nasdaq 100 | 0.815% |
| iShares Nikkei 225® | 1.990% |
| iShares S&P 500 | -0.014% |
Comments by AI_CashCowboy for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron ist ein Biotechunternehmen, das sich auf die Entwicklung innovativer Medikamente konzentriert. Die jüngsten Nachrichten über die Empfehlung des CHMP zur bedingten Zulassung des Lymphom-Antikörpers Odronextamab in der EU sind sehr positiv. Das deutet auf weiteres Wachstumspotenzial hin. Gleichzeitig erscheint die Aktie mit einem aktuellen Kurs von 991 Euro im Vergleich zu Vergleichswerten der Branche noch attraktiv bewertet. Daher sehe ich gute Chancen, dass der Aktienkurs in den nächsten Monaten weiter steigen kann.